Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Bella Kaufman; Steven Stein; Michelle A. Casey; Beth O. Newstat

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Bella Kaufman^*, Steven Stein, Michelle A. Casey, Beth O. Newstat

^*Corresponding author for this work

Oncology

GlaxoSmithKline

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP). An updated analysis in 399 women supports the earlier findings. In this updated analysis, TTP (hazard ratio [HR] 0.57) favored lapatinib plus capecitabine. Survival trended in favor of the combination. The incidence of cardiac events was numerically higher in the combination arm (5 cases in the combination arm, 2 cases in the monotherapy arm).

Original language	English
Pages (from-to)	61-66
Number of pages	6
Journal	Biologics: Targets and Therapy
Volume	2
Issue number	1
State	Published - 2008

Keywords

Breast cancer
Capecitabine
HER2
Lapatinib

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{95b4ca6743f24d22838c310ccc06a852,

title = "Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer",

abstract = "Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP). An updated analysis in 399 women supports the earlier findings. In this updated analysis, TTP (hazard ratio [HR] 0.57) favored lapatinib plus capecitabine. Survival trended in favor of the combination. The incidence of cardiac events was numerically higher in the combination arm (5 cases in the combination arm, 2 cases in the monotherapy arm).",

keywords = "Breast cancer, Capecitabine, HER2, Lapatinib",

author = "Bella Kaufman and Steven Stein and Casey, {Michelle A.} and Newstat, {Beth O.}",

year = "2008",

language = "אנגלית",

volume = "2",

pages = "61--66",

journal = "Biologics: Targets and Therapy",

issn = "1177-5475",

publisher = "Dove Medical Press Ltd.",

number = "1",

}

TY - JOUR

T1 - Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

AU - Kaufman, Bella

AU - Stein, Steven

AU - Casey, Michelle A.

AU - Newstat, Beth O.

PY - 2008

Y1 - 2008

N2 - Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP). An updated analysis in 399 women supports the earlier findings. In this updated analysis, TTP (hazard ratio [HR] 0.57) favored lapatinib plus capecitabine. Survival trended in favor of the combination. The incidence of cardiac events was numerically higher in the combination arm (5 cases in the combination arm, 2 cases in the monotherapy arm).

AB - Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP). An updated analysis in 399 women supports the earlier findings. In this updated analysis, TTP (hazard ratio [HR] 0.57) favored lapatinib plus capecitabine. Survival trended in favor of the combination. The incidence of cardiac events was numerically higher in the combination arm (5 cases in the combination arm, 2 cases in the monotherapy arm).

KW - Breast cancer

KW - Capecitabine

KW - HER2

KW - Lapatinib

UR - http://www.scopus.com/inward/record.url?scp=78049469912&partnerID=8YFLogxK

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:78049469912

SN - 1177-5475

VL - 2

SP - 61

EP - 66

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

IS - 1

ER -

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this